New pill could offer hope for advanced breast cancer patients
Disease control
Completed
This Phase 3 trial compares a new hormone therapy pill called elacestrant to standard treatments (fulvestrant or aromatase inhibitors) in 478 people with ER+/HER2- advanced breast cancer that worsened after prior CDK4/6 inhibitor therapy. The study measures how long the cancer st…
Phase: PHASE3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC